EU Warns Novo's Ozempic May Cause Rare Serious Eye Disorders
The European Medicines Agency has confirmed that Novo Nordisk's drugs Ozempic and Wegovy, containing semaglutide, may very rarely cause a serious eye condition leading to vision loss, affecting up to 1 in 10,000 users, prompting updates to drug labels while maintaining the drugs' overall benefit-risk profile.